高级检索
当前位置: 首页 > 详情页

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Oncology,First Affiliated Hospital, Guangzhou University of Chinese Medicine [2]Department of Preventive Medicine and Biostatistics ,School of Basic Medical Science, Guangzhou University of Chinese Medicine [3]Department of Oncology,Guangzhou Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China
出处:
ISSN:

关键词: Primary liver cancer cancer pain Shuangbai San quality of life

摘要:
Context. Shuangbai San is a Chinese herb preparation used externally to treat pain. There have been few randomized controlled trials addressing the safety and usefulness of Shuangbai San, such as its effect on pain relief and quality of life (QOL) improvement. Objectives. This study was conducted to evaluate the effect of Shuangbai San on relieving pain and improving QOL in primary liver cancer patients with cancer pain. Methods. A total of 134 primary liver cancer patients with mild pain (numerical rating scale [NRS] #3), either locally in the liver or in the upper abdomen, were enrolled and randomly allocated to the group receiving Shuangbai San or the control group (receiving placebo). The primary outcome measures were the NRS score and QOL scales, including the QOL scale for patients with liver cancer, version 2.0 and the European Organization for Research and Treatment of Cancer QOL Questionnaire-C30. The secondary outcome measures included the Karnofsky Performance Status score, blood indicators, and liver and kidney function before and after treatment. Results. The NRS scores decreased more significantly in the Shuangbai San group than in the placebo group (P < 0.05) at the corresponding time points. The changes in the scores for the physical function, psychological function, and symptoms/adverse effects domains of the QOL scale for patients with liver cancer, version 2.0 and the physical, emotional, and cognitive domains of the European Organization for Research and Treatment of Cancer QOL Questionnaire-C30 were significantly greater in the Shuangbai San group than in the placebo group (P < 0.05). The changes in the scores for the other domains were not significantly different (P > 0.05). Conclusion. The use of Shuangbai San can relieve mild pain in liver cancer patients and improve their QOL. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 3 区 医学
小类 | 3 区 临床神经病学 3 区 卫生保健与服务 3 区 医学:内科
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 临床神经病学 2 区 卫生保健与服务 2 区 医学:内科
JCR分区:
出版当年[2014]版:
Q1 HEALTH CARE SCIENCES & SERVICES Q1 MEDICINE, GENERAL & INTERNAL Q2 CLINICAL NEUROLOGY
最新[2023]版:
Q1 HEALTH CARE SCIENCES & SERVICES Q1 MEDICINE, GENERAL & INTERNAL Q2 CLINICAL NEUROLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者机构: [1]Department of Oncology,First Affiliated Hospital, Guangzhou University of Chinese Medicine
通讯作者:
通讯机构: [1]Department of Oncology,First Affiliated Hospital, Guangzhou University of Chinese Medicine [*1]Department of Oncology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Airport Road, Guangzhou, Guangdong, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号